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“A 56-year-old woman with advanced, incurable ovarian 
cancer was invited to be the first patient, in the first dose 
level, of a phase I trial of a new drug that was being given 
to patients for the first time. The patient information sheet 
stated that she was unlikely to benefit from her participation 
in the trial, and she was told that when phase I trials are 
initiated, the drug concentration is usually significantly less 
than the final recommended dose or maximum tolerated 
dose of the compound. The patient was concerned about 
not obtaining a tumour response with the lower dose level, 
and asked if she could delay participation until higher dose 
cohorts had opened for accrual” [1].
  This episode is emblematic and poses, in my opinion, 
a number of key ethical questions. Are, for example, phase 
I trials always in the patient’s interest? Is the safety require-
ment that is tested in phase I trials really an advantage 
for patients? Perhaps, instead of a dose escalation, the best 
guess approach for cancer patients would be more in their 
interest? Should it not be the patient who, after being fully 
informed, decides and tailors the therapy according to a 
risk evaluation that encompasses his or her specific situation 
(emotional, familiar, and clinical)? Why shouldn’t a patient 
with an incurable terminal disease be able to choose for 
himself or herself the level of risk to take in the hope 
of gaining some benefit?
  Maybe patients’ voices should be listened to more often 
and they should, after being appropriately and completely 
informed about a new trial’s risks/benefits, be able to decide, 
with their doctor’s support, the level of risk to which they 
should be exposed. An interesting study from Manish 
Agrawal’s group showed that for 63% of patients, the most 
important information for decision making was the fact 
that phase I drugs killed cancer cells, whereas only 12% 
considered drug adverse effects as the most useful infor-
mation. In the same study, more than 90% of patients said 
they would still participate in a study even if the ex-
perimental drug caused serious adverse effects, including 
a 10% chance of dying [2]. 
  In 1936, the US government instituted the federal registers 
to record regulations. The main objective was to protect 
consumers. Nowadays, regulatory agencies are developing 
and growing in number. Philosophically, the presence of 
regulatory agencies is very important for protecting consum-
er and patient health; moreover, in the biomedical scientific 
field, the presence of a third party committed to defending 
and protecting patients from biotech economic interests 
and speculations is of great value.
  However, currently, the regulatory steps for clinical ap-
proval of a new drug are so numerous that often there 
is a considerable delay from when the drug is ready to 
be tested to when the investigational new drug (IND) appli-
cation is ready to be filed. Furthermore, before the Kefauver 
Harris Amendment ratification in 1962, the average time 
from filing an IND application to gaining approval was 
7 months. By 1998, it took an average of 7.3 years from 
the time of filing to the time of approval [3].
  In February 1999, during the television show “Take it 
to the limits,” the economist Milton Friedman argued that, 
while all the regulatory agencies are concerned with the 
safe usage of new drugs, the delays in the approval process 
have cost lives. This was proved in 1990 by Louis Lasagna, 
then chairman of a presidential advisory panel on drug 
approval, who estimated that thousands of lives were lost 
each year due to delays in the approval and marketing Korean J Hematol 2010;45:145-6.
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of drugs for cancer and AIDS. Subsequently, the FDA in-
troduced on their website an expedited approval of drugs 
for life-threatening diseases and expanded pre-approval ac-
cess to drugs for patients with limited treatment options.
  The worldwide growth of diversified regulatory agencies 
has created another phenomenon: the huge discrepancy 
regarding the possible therapeutic choice for patients, de-
pending mostly on the country they live in. This again 
limits the power of patient choice. Why, for example, is 
an adaptive therapy more efficient or more toxic for a 
German pancreatic cancer patient than for one from Italy? 
While it is impossible to argue about the importance of 
the FDA developing effective global risk control on the 
food industry in order to ensure greater safety for consumers 
with respect to suspect food on the market, it is definitively 
more difficult to assess the benefit and the main focus of 
reducing of all kinds of risks for terminal patients.
  Historically, medicine has always improved thanks to 
clinical experimentation. If we consider most of the key 
drugs and medical procedures that are successfully used 
in the clinic nowadays, they would never pass the require-
ments needed to complete a successful IND application for 
a regulatory agency like the FDA in the United States in 
order to allow a phase I clinical trial [4]. As a practical 
example, let’s just think about a bone marrow trans-
plantation procedure to produce new blood cells. This ther-
apy, which uses bone marrow-derived stem cells, was ini-
tiated in 1950 by the Nobel Prize winning E. Donnall 
Thomas’s team at the Fred Hutchinson Cancer Research 
Centre. However, one of the recurrent major and life-threat-
ening complications that occur as a consequence of this 
widely adopted procedure is graft-versus-host disease 
(GVHD). GVHD is an inflammatory disease that is unique 
to allogeneic transplantation. 
  This type of therapy would never be introduced into 
clinic practice today, prohibited by the stringent safety cri-
teria adopted in the new phase I studies.
  In an era in which medicine is moving toward personal-
ized solutions, where we start to fully appreciate the differ-
ences in the unique biological response of every single pa-
tient to treatments, we translate this highly innovative vision 
of the individuality of each single patient and disease to 
standardized, highly conservative phase I criteria that is 
the major obstacle to a more effective bench to bedside 
translational research. The main goal for patients and physi-
cians should be fighting cancer, and almost no adverse effect, 
including death, should dissuade terminal patients from en-
rolling in promising phase I trials. This idea and the data 
obtained by Agrawal’s group are in open disagreement with 
the bureaucratic system that delegates the responsibility 
of risk decision making to third parties made up of govern-
ment employees who often have never worked in a clinic 
or in research, and who lack practical clinical research expe-
rience to effectively judge the consequences of a trial. The 
economist Milton Friedman has claimed that the regulatory 
process is inherently biased against approval of some worthy 
drugs, because the adverse effects of wrongfully banning 
a useful drug are undetectable, whereas the consequences 
of mistakenly approving a harmful drug are highly publi-
cized. Therefore, the FDA will take actions that will result 
in the least public condemnation, regardless of the health 
consequences [5]. This observation underlines once again 
that safety is probably a more important endpoint for regu-
latory agencies than it is for patients.
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